Otley C C, Fewkes J L, Frank W, Olbricht S M
Department of Dermatology, Harvard Medical School, Boston, Mass., USA.
Arch Dermatol. 1996 Feb;132(2):161-6.
No controlled studies exist with regard to the risks of continuing therapy with warfarin sodium or platelet inhibitors or the benefits of briefly discontinuing therapy with these agents in patients who are undergoing cutaneous surgical procedures. Our objective was to determine the frequency of complications of cutaneous surgery in patients who were receiving warfarin or platelet inhibitors and to evaluate whether preoperative discontinuation reduces complications. A retrospective, controlled study was performed of complications of excisional and Mohs micrographic surgery in 653 patients who were being treated with warfarin or platelet inhibitors or with their medications being briefly withheld.
Severe complications of cutaneous surgery in patients who are taking warfarin or platelet inhibitors are uncommon, occur in 1.6% of cases, and are not significantly increased compared with complications in control subjects. Furthermore, there was no statistically significant reduction in the rates of severe complications in patients who had their medications preoperatively held.
Cutaneous surgery in patients who receive warfarin or platelet inhibitors is associated with a low risk of severe complications, not significantly reduced by brief preoperative discontinuation.
对于正在接受皮肤外科手术的患者,尚无关于继续使用华法林钠或血小板抑制剂治疗的风险,或短期停用这些药物的益处的对照研究。我们的目的是确定接受华法林或血小板抑制剂治疗的患者皮肤手术并发症的发生率,并评估术前停药是否能减少并发症。我们对653例正在接受华法林或血小板抑制剂治疗或短期停药的患者进行了一项回顾性对照研究,观察切除手术和莫氏显微外科手术的并发症情况。
服用华法林或血小板抑制剂的患者皮肤手术严重并发症并不常见,发生率为1.6%,与对照组相比,并发症并未显著增加。此外,术前停药患者的严重并发症发生率在统计学上没有显著降低。
接受华法林或血小板抑制剂治疗的患者进行皮肤手术,严重并发症风险较低,术前短期停药并不能显著降低该风险。